Albumin Administration in Neonates: Do Not Use
Albumin should not be administered to neonates for any routine indication, including volume replacement, respiratory support, or hypoalbuminemia correction. 1
Primary Contraindication
Preterm neonates (≤36 weeks gestation) – The American College of Chest Physicians explicitly recommends against albumin use to improve respiratory function or for volume replacement in infants ≤32 weeks or ≤1,500 g, regardless of perfusion status (evidence certainty: very low). 1
All neonatal populations – Crystalloid solutions (isotonic balanced crystalloids such as lactated Ringer's) are the preferred first-line therapy for plasma volume expansion rather than albumin. 1
Evidence Against Neonatal Albumin Use
No benefit for hypotension – Studies demonstrate that albumin is not indicated in neonates for initial treatment of hypotension; crystalloid infusion should be used first, with albumin considered only after crystalloid failure. 2
No benefit for respiratory distress – Albumin does not improve respiratory outcomes in preterm infants with respiratory distress and hypoalbuminemia. 3, 2
Hypoalbuminemia alone is not an indication – The practice of giving albumin to correct "asymptomatic" hypoalbuminemia should be discouraged; low serum albumin alone does not justify albumin administration. 1, 3, 2
No benefit at resuscitation – Albumin should not be used during delivery room resuscitation. 4, 3
Limited Exception: Severe Hyperbilirubinemia
Pre-exchange transfusion albumin – The only scenario where albumin may have a role is in severe hemolytic disease awaiting exchange transfusion, where albumin may reduce free bilirubin levels. 5
Conflicting evidence on efficacy – One study showed that 1 g/kg of 20% albumin one hour before exchange transfusion reduced post-exchange bilirubin and phototherapy duration. 6 However, a higher-quality randomized trial found no superiority of albumin over equi-volume saline in reducing post-exchange phototherapy duration or bilirubin mass removed in non-hemolytic hyperbilirubinemia. 7
Current recommendation – Given the conflicting evidence and the contraindication for routine neonatal use, albumin for hyperbilirubinemia should be reserved only for severe hemolytic disease in consultation with neonatology, not for non-hemolytic hyperbilirubinemia. 5, 7
Administration Method (If Exceptionally Used)
If albumin must be administered in the rare exception of severe hemolytic disease:
Concentration – Use 20% or 25% human albumin solution. 5
Dose – 1 g/kg (equivalent to 5 mL/kg of 20% albumin) administered one hour prior to exchange transfusion. 6, 7
Route – Always administer by slow intravenous infusion. 5
Rate – In hypoproteinemic patients, the rate should not exceed 2 mL per minute, as more rapid injection may precipitate circulatory embarrassment and pulmonary edema. 5
Dilution – May be administered undiluted or diluted in 0.9% sodium chloride or 5% dextrose in water; if sodium restriction is required, use only 5% dextrose in water. 5
Needle size – Only 16-gauge needles or dispensing pins should be used with 20 mL vial sizes and larger, inserted perpendicular to the stopper within the raised ring area. 5
Critical Safety Concerns
Pulmonary edema risk – Rapid infusion of 25% albumin in hypoproteinemic patients (which includes most neonates) can precipitate pulmonary edema. 1, 5
Increased capillary permeability – In neonates with hypoalbuminemia and increased capillary permeability (common in critical illness), albumin supplementation often leads to greater albumin leakage across the capillary membrane, contributing to edema formation without improvement in outcome. 2
Cost without benefit – Albumin costs approximately US $130 per 25 g, substantially higher than crystalloids, with no proven clinical benefit in neonatal scenarios. 1